2026-03-02
Ozempic Face Is Filling Med Spa Schedules—Here's the Clinical and Business Case
GLP-1 drugs are projected to hit $45B+ in 2026 revenue—and they're sending patients straight to med spas with significant facial volume loss. Here's what clinicians, analysts, and patients need to know.
Read more →